Clinical Research Directory
Browse clinical research sites, groups, and studies.
Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes
Sponsor: Universitaire Ziekenhuizen KU Leuven
Summary
Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.
Official title: Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes: a Double Blind RCT
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
252
Start Date
2023-09-14
Completion Date
2028-12
Last Updated
2025-02-10
Healthy Volunteers
No
Interventions
Semaglutide Pen Injector
maintenance dose of 1mg SC once weekly
Semaglutide placebo
maintenance dose of 1mg SC once weekly
Locations (13)
OLV-Aalst-Asse
Aalst, Belgium
UZA
Antwerp, Belgium
ZNA,
Antwerp, Belgium
AZ St Jan Brugge
Bruges, Belgium
Erasme
Brussels, Belgium
UZ Brussel
Brussels, Belgium
Jan Yperman
Ieper, Belgium
AZ Groeninge Kortrijk
Kortrijk, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liège
Liège, Belgium
Centre Hospitalier Mouscron
Mouscron, Belgium
Vitaz
Sint-Niklaas, Belgium
AZ Turnhout
Turnhout, Belgium